News | Vascular Access | October 04, 2017

TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System

4 French catheter system creates an endovascular hemodialysis access with a streamlined procedure

TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System

October 4, 2017 — TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The technology uses a 4 French catheter system with enhanced visual indicators to create hemodialysis access using an endovascular technique without open surgery.

In a prospective, single arm, single-center study evaluating the everlinQ 4 endoAVF System, 97 percent of endovascular arteriovenous fistula  (endoAVF) procedures were successful, and fistula maturation was achieved in 83 percent of patients.

Tobias Steinke, M.D., chief of vascular and endovascular surgery, Schön Klinik, Düsseldorf, Germany,performed the first case in Europe using the everlinQ 4 System. “The new system with smaller profile catheters and radiopaque visual indicators was extremely easy to use,” he said. “This new approach streamlines the procedure for providing patients a functional AV fistula without open surgery.”

Each year approximately 3 million people worldwide with end-stage renal disease (ESRD) are treated with hemodialysis.1 However, the first step, creating a viable access in the arm, is often a significant clinical challenge. The current standard approach, surgical arteriovenous fistulas (AVFs), are associated with high failure rates2, and may require frequent revisions, impacting patient quality of life and resulting in unnecessary costs.3

The everlinQ endoAVF System, using the 4 French or 6 French catheter system, is designed to create an AVF for hemodialysis access using an endovascular approach. In the procedure, two thin, flexible magnetic catheters are inserted into an artery and vein in the arm. A small amount of radiofrequency energy is used to connect the artery and vein to create the fistula. The catheters are then removed and a brachial vein is coil-embolized, enabling future dialysis.  

The 6 French everlinQ endoAVF System previously received CE marking for ESRD patients who need hemodialysis. The 6 French system also has Health Canada Medical Device License. TVA Medical is pursuing U.S. Food and Drug Administration (FDA) clearance of the everlinQ endoAVF System and the technology is not currently available for use in the United States.

For more information: www.tvamedical.com
 
References

 
1 Liyanage, et al.  Lancet, 2015. 10.1016/S0140-6736
2 Al-jaishi, et al.  Am J Kidney Dis 2014;63:464-78.
3 Lok. Clin J Am Soc Nephrol 2: 1043-1053, 2007.

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init